GlassScriptPhysician profile
Annie M Jackson
NPI 1891839866
$2,827.10
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $546 · 2021: $443 · 2022: $593 · 2023: $64.27 · 2024: $17.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $703.34 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $220.39 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $193.58 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $165.87 | 2019-2023 | |
| Abbvie INC. | $159.97 | 2021-2022 | |
| Lilly USA, LLC | $158.48 | 2019-2022 | |
| Genzyme Corporation | $124.16 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $119.49 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $103.14 | 2019-2021 | |
| Ucb, INC. | $100.14 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $96.52 | 2019 | |
| Avanir Pharmaceuticals, INC. | $80.43 | 2019-2022 | |
| Eisai INC. | $78.56 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.52 | 2020 | |
| Adamas Pharmaceuticals, INC. | $54.85 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.31 | 2019-2022 | |
| Amgen INC. | $47.49 | 2019-2021 | |
| Greenwich Biosciences, INC. | $36.35 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $31.61 | 2021 | |
| Csl Behring | $26.12 | 2022 | |
| Genentech USA, INC. | $24.68 | 2019 | |
| Pfizer INC. | $23.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.56 | 2021 | |
| Ge Healthcare | $17.52 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.26 | 2022 | |
| Boston Scientific Corporation | $17.22 | 2024 | Advantage System |
| Sk Life Science, INC. | $15.82 | 2022 | |
| Biogen, INC. | $14.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.19 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.11 | 2022 | |
| Grifols USA, LLC | $11.89 | 2019 | |
| Zyla Life Sciences, INC. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.